Holen Sie sich die Stockscreener-App
0.8436
8.88%
0.0688
Vorhandelsmarkt:
.92
0.0764
+9.06%
Rein Therapeutics Inc Aktie (RNTX) Neueste Nachrichten
Rein Therapeutics Inc (NASDAQ: RNTX) Stock Price, News & Analysis - kalkine.ca
Rein (RNTX) Quarter in Focus: The Available Earnings Metric Delivers a Beat on the Day; Post-Report: Shares Move 0.88% Higher in the Current UpdateGuidance Accuracy Score - vinanet.vn
Rein Therapeutics receives FDA fast track for IPF drug LTI-03 - Investing.com Australia
Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis - The Manila Times
Rein Therapeutics Receives FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis - Quiver Quantitative
Rein Therapeutics Receives U.S. FDA Fast Track Designation For Lti-03 In Idiopathic Pulmonary Fibrosis - TradingView
FDA grants Fast Track designation to inhaled treatment for lung disease with 3-to-5-year median survival - Stock Titan
Equities Analysts Set Expectations for RNTX FY2026 Earnings - MarketBeat
What is HC Wainwright's Estimate for RNTX FY2030 Earnings? - MarketBeat
RNTX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $8.00 - GuruFocus
Rein Therapeutics (NASDAQ:RNTX) Given "Buy" Rating at HC Wainwright - MarketBeat
H.C. Wainwright reiterates Buy on Rein Therapeutics stock By Investing.com - Investing.com Canada
RNTX Q1 2026 Earnings: Narrower-Than-Expected Loss Beats Estimates as Stock Climbs 2.35%Tech Earnings Analysis - Vinanet
Rein Therapeutics (NASDAQ:RNTX) Announces Earnings Results - MarketBeat
Rein Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Rein Therapeutics (RNTX) Holds at $0.79 as Range-Bound Trading PersistsVWAP Bounce - Vinanet
Rein Therapeutics Raises $44.3 Million in Public Offering - Minichart
Rein Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Rein Therapeutics Surpasses 25% Enrollment in Phase 2 RENEW Trial of LTI-03 for IPF, Completes $57.5 Million Public Offering - Quiver Quantitative
Press Release: Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - Moomoo
Rein Therapeutics 2Q 2026: Revenue $0 Net loss $6.4M, EPS $(0.10) — 10-Q Summary - TradingView
RNTX: Q2 net loss narrowed, liquidity strengthened, and Phase 2 LTI-03 trial remains on track - TradingView
Rein Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Rein Therapeutics Inc. (NASDAQ:RNTX) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
RNTX Q1 2026 Earnings: Narrowed Per-Share Loss Beats Consensus by Nearly 62%Financial Health Score - vinanet.vn
RNTX Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Improved Capital DisciplineOne-Time Loss Impact - vinanet.vn
Rein Therapeutics (NASDAQ:RNTX) Shares Down 2.9%Here's Why - MarketBeat
Rein Therapeutics Inc expected to post a loss of 17 cents a shareEarnings Preview - TradingView
Rein Therapeutics Inc (RNTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Certain Stock Options of Rein Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 9-AUG-2026. - marketscreener.com
Certain Warrants of Rein Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 9-AUG-2026. - marketscreener.com
Rein Therapeutics Inc (RNTX) Stock News Today - TradingKey
RNTX PE Ratio & Valuation, Is RNTX Overvalued - Intellectia AI
Rein Therapeutics’ LTI-03 study published in Nature Communications - Investing.com
Rein Therapeutics’ LTI-03 study published in Nature Communications By Investing.com - Investing.com Canada
Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications - Yahoo Finance
Rein's Inhaled LTI-03 Reduced Lung-Scarring Markers After 14 Days - Stock Titan
Rein Therapeutics (RNTX) Dips 2.76% to $0.74, Pressing Against Key SupportSuperTrend - dars.gov.et
Rein Therapeutics Inc (RNTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Rein Therapeutics Inc (RNTX) Cash Flow - TradingKey
Rein Therapeutics Inc (RNTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Rein Therapeutics Inc (RNTX) Income Statement - TradingKey
Rein Therapeutics Inc (RNTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
RNTX|Rein Therapeutics Inc|Price:0.791|Chg%:-0.009 - TradingKey
Rein Therapeutics Inc (RNTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Rein Therapeutics (RNTX) Proxy filing Summary - Quartr
Rein Therapeutics, Inc. Revenue Breakdown – NASDAQ:RNTX - TradingView
RNTX Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive SurpriseFree Cash Flow Trends - vinanet.vn
Rein Therapeutics Inc. (RNTX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Rein Therapeutics (RNTX) Q4 2025 earnings summary - Quartr
Rein Therapeutics (RNTX) Tests Key Support as Shares Edge LowerHigh Low Breadth - vinanet.vn
Stock Ratings | Morgan Stanley raised its target price for Intel (INTC) to $75; Maxim Group initiated coverage on Rein Therapeutics (RNTX) with a target price of $4, representing a potential gain of 373.93%. - Sahm
symbol__ Stock Quote Price and Forecast - CNN
Rein Therapeutics Shareholders Approve Governance and Stock Changes - TipRanks
Rein Therapeutics expands phase 2 IPF trial to Germany By Investing.com - Investing.com South Africa
Rein Therapeutics expands phase 2 IPF trial to Germany - Investing.com
Rein Therapeutics Completes Global Expansion of Phase 2 IPF Trial - marketscreener.com
Rein Therapeutics Announces Phase 2 RENEW Trial Now Enrolling Across All Five Countries - GlobeNewswire
Rein Therapeutics Price Target Announced at $4.00/Share by Maxim Group - Moomoo
Rein Therapeutics (RNTX) Gains Buy Rating and $4 Price Target fr - GuruFocus
RNTX Initiates Coverage On by Maxim Group -- Rating Set to Buy - GuruFocus
Rein Therapeutics (RNTX) AGM 2026 Summary - Quartr
Transcript : Rein Therapeutics Inc.Shareholder/Analyst Call - marketscreener.com
0.64%
0.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):